Successful Treatment of Recurrent Biliary Anastomotic Stricture with Drug-coated Balloon Dilation Authors: Malcolm Guan Hin Yeo, Hao Xiang Published: 2026 ABSTRACT AbstractBiliary-enteric anastomotic strictures are a well-recognized post-surgical complication that can recur despite multiple interventions. In this case report, we describe the successful use of paclitaxel-coated balloon dilation in treatment of a biliary anastomotic stricture. A 72-year-old woman presented with a recurrent benign biliary stricture post-hepatico-jejunostomy for cholangiocarcinoma, despite endoscopic and percutaneous balloon dilation. Over 3 years, she had visited our hospital on 10 occasions for cholangitis secondary to her stricture. She was then treated with paclitaxel-coated balloon dilation, and her stricture has remained patent for the past 2 years without further hospital visitations.Keywords: paclitaxel-coated balloon, biliary stricture, balloon dilation, anastomotic stricture Introduction Biliary-enteric anastomotic strictures are a well-recognized post-surgical complication that often results in recurrent cholangitis and obstructive jaundice. Untreated and persistent blockage at the anastomosis site can lead to life-threatening complications such as sepsis, liver abscesses, and secondary biliary cirrhosis. The first-line intervention in many institutions is cholangiography and balloon dilation, sometimes followed by long-term passive dilation with stent or biliary drain placement. However, balloon dilation alone is associated with high recurrence rates [1], while stent placement carries additional risks of complications [2] and long-term biliary drain placement is cumbersome and negatively impacts the patient’s quality of life [3]. The use of drug-coated balloons has been established as an effective pharmacological adjunct to help achieve long-term patency in vascular interventions such as in coronary arterial disease [4]. Recently, its off-label use in non-vascular interventions such as stricture management has been explored, with promising results [5]. We conducted a literature review on PubMed and Embase using search terms related to drug-coated balloon therapy in biliary strictures and identified two relevant peer-reviewed full-text articles. We identified one case study [6] and one prospective pilot study [7] involving the endoscopic use of paclitaxel-eluting balloon dilation in anastomotic biliary strictures. The pilot study enrolling 13 patients treated for biliary anastomotic strictures post-liver transplantation with endoscopic paclitaxel-eluting balloon dilation. Twelve (12) out of 13 patients achieved long-term clinical success (defined as no intervention required for at least 24 months) and nine patients only required a single balloon dilation to achieve this. While the above studies demonstrate the effectiveness of paclitaxel-eluting balloon dilation, they describe an endoscopic approach to management and focus exclusively on post-liver transplantation patients who would be receiving immunosuppressive therapy. In this case, we describe the successful percutaneous approach of paclitaxel-coated balloon dilation to treat a non-transplant anastomotic biliary stricture refractory to repeated balloon dilation and biliary drain placement. Case Description Our patient was a 72-year-old woman who presented with a recurrent benign biliary stricture post-hepatico-jejunostomy for resection of cholangiocarcinoma. Her medical history was significant for rheumatoid arthritis and anti-phospholipid syndrome, on lifelong warfarin therapy in the context of a previous unprovoked pulmonary embolism. In August 2019, she underwent an extended left hemi-hepatectomy for resection of a T2b perihilar cholangiocarcinoma. During the procedure, a Roux-en-Y hepatico-jejunostomy was performed and two right-sided bile ducts were anastomosed to the roux loop. Her admission was complicated by a small bile duct leak which was managed conservatively with a post-operative Blake drain left in-situ on discharge from hospital. This was removed 6 weeks later. In December 2019, she visited the emergency department with a fever of 39.4°C. At the time of visitation, her bilirubin was 39 μmol/L (2.28 mg/dL), alkaline phosphatase 226 U/L, gamma-glutamyl transferase 280 U/L, alanine aminotransferase 117 U/L, aspartate aminotransferase 89 U/L. She was diagnosed with biliary sepsis and treated with intravenous amoxicillin before being stepped down to oral amoxicillin-clavulanate. In the months following, she had multiple similar admissions for cholangitis and biliary sepsis. CT of her abdomen and pelvis and magnetic resonance cholangiopancreatography imaging showed moderate intrahepatic biliary duct dilation in segments 6 and 7, suggestive of a stricture at the level of her right posterior duct hepatico-jejunostomy site (Figures 1A-B and 2). (A) Oblique sagittal image of a CT-AP performed in May 2020 showing the dilated intrahepatic bile ducts (red arrow) representing a stricture at the posterior hepatico-jejunostomy site. (B) Axial image from CT-AP performed in May 2020 showing the dilated intrahepatic bile ducts (red arrow) representing a stricture at the posterior hepatico-jejunostomy site. CT-AP: CT of abdomen and pelvis Radial MIP of the biliary tree from MRCP performed in October 2020 showing a tight stricture at the anastomosis (red arrow). MRCP: magnetic resonance cholangiopancreatography In January 2021, percutaneous cholangiography was attempted on three separate occasions; however, in each instance, the guidewire was unable to pass through the stricture (Figure 3). She was ultimately managed with a percutaneous biliary drain above her stricture. Cholangiogram from one of the initial attempts to cross the stricture in January 2021. This shows a tight stricture at the hepatico-jejunostomy and dilated bile ducts. No contrast is seen crossing into the jejunum despite forceful injection. Several months later, she underwent a laparotomy with successful endoscopic plain balloon dilation of her anastomoses in June 2021. Her posterior anastomosis was dilated from 1 mm to 5 mm. However, she continued to present with further episodes of cholangitis and underwent further plain balloon dilation of her stricture percutaneously with a Mustang balloon (Boston Scientific, Marlborough, MA, USA) in March 2022, where it was successfully dilated with 4 mm and 8 mm balloons. A 10 Fr drainage tube with extra side holes was left across the stricture. She visited 2 months later in May 2022 with cholangitis and again underwent repeat percutaneous plain balloon dilation with a Mustang balloon, where the stricture was dilated to 10 mm. She continued to visit our hospital for scheduled cholangiograms and biliary catheter changes every 4 weeks under conscious sedation. Her drainage tube was gradually upsized to a 14 Fr catheter (Resolve, Merit Medical, South Jordan, UT, USA). During these sessions, she also underwent high-pressure balloon dilation of her anastomosis twice (Conquest, Becton Dickinson, Franklin Lakes, NJ, USA), in July 2022 and September 2022. In June 2023, after more than 1 year of passive dilation, her large-bore 14 Fr catheter was removed and replaced with a 10.2 Fr drainage catheter (Dawson-Mueller, Cook Medical, Bloomington, IN, USA) placed above her anastomosis to test its patency. Her cholangiogram performed 4 weeks later demonstrated recurrence of her stricture (Figure 4). Given repeated failure of plain balloon dilation and long-term passive dilation, she was planned for dilation with a cutting and drug-coated balloon. Still image from the cholangiogram in July 2023, 4 weeks after the 14 Fr drainage tube was removed. Sheath injection above the stricture shows recurrence with only minimal trickle flow into the jejunum. An 8 mm × 20 mm peripheral cutting balloon (Boston Scientific, Marlborough, MA, USA) was first deployed using a V18 guidewire system (ControlWire Guidewire, Boston Scientific, Marlborough, MA, USA) across the stricture and inflated before and after rotation. This was followed by an 8 mm × 40 mm Ranger paclitaxel-coated balloon (Boston Scientific, Marlborough, MA, USA) which was inflated for 2.5 minutes (Figures 5A-C). (A) Planning fluoroscopy image of the stricture prior to ballooning. (B) Fluoroscopy image showing 8 mm cutting balloon deployment and inflation. (C) Fluoroscopy image showing 8 mm drug-coated balloon deployment and inflation. Her repeat cholangiogram 4 weeks post-intervention showed patent anastomosis and her external biliary drain was removed (Figure 6). The cholangiogram 4 weeks post-intervention shows a widely patent anastomosis with brisk free flow into the jejunum. She had no further presentations for cholangitis and her repeated CT cholangiogram in April 2025 and November 2025 both showed stable narrowing at her anastomosis which otherwise remained patent 2 years post-intervention without intrahepatic duct dilatation (Figure 7A and B). Her most recent serum bilirubin at that time was 10 μmol/L (0.58 mg/dL). (A) Oblique sagittal image from CT cholangiogram in November 2025, 2 years post-intervention, showing non-dilated intrahepatic bile ducts (red arrow) and a patent hepatico-jejunostomy with contrast in the small bowel (yellow arrow). (B) Axial image from CT cholangiogram in November 2025, 2 years post-intervention, showing non-dilated intrahepatic bile ducts (red arrow) and a patent hepatojejunostomy with contrast in the small bowel (yellow arrows). In total, she had five plain balloon dilations, including two high-pressure balloon dilations, and passive dilation with a drainage tube for more than 1 year. She had a total of 10 presentations to our hospital for cholangitis/biliary sepsis, including one admission to intensive care unit before her final treatment with the drug-coated balloon. Discussion This case illustrates a successful usage of a percutaneous paclitaxel-coated balloon to treat an anastomotic biliary stricture after repeated failure of plain balloon dilation and long-term passive dilation. Standard first-line treatment of benign biliary strictures is with plain balloon dilation. This can be conducted endoscopically or percutaneously; however, alteration of the normal bowel anatomy after surgery (e.g., hepatico-jejunostomy) commonly make endoscopy challenging without laparotomy assistance. Plain balloon dilation remains the least-invasive treatment option, but is also associated with high rates of restenosis, up to 47% [1]. Balloon dilation is commonly followed with long-term passive dilation, such as with large-bore percutaneous biliary catheters. The success rate for this approach has been reported to be 81.25% in post-transplant patients and 89.5% in non-transplant patients at a mean follow-up of 20 months, with specialized dual-catheter techniques achieving up to 91% patency at 3 years [8]. However, this approach requires multiple procedures to upsize the catheter size every 2-4 weeks, followed by regular maintenance exchanges for at least 12 months. The presence of indwelling catheters can also negatively impact a patient’s quality of life and cause pain with liver movements during normal activities [3], while exposing patients to risks of complications such as infection or tube displacement [9]. Stent placement is another option for long-term passive dilation, which can be covered metal, self-expandable metal stents, or multiple plastic stents. This option has a higher success rate compared to plain balloon dilation alone [8] and self-expandable metal stents have been found to be superior to biliary catheter placement [10]. At the same time, however, stents are also associated with higher rates of complications including stent migration, biofilm accumulation and blockage, and embedment into the duct wall [2]. These interventions are purely mechanical in their approach to treating strictures. In contrast, the use of drug-coated balloons acts as a pharmacological adjunct to further reduce risk of re-stenosis. The most commonly used drug is paclitaxel, although other options such as sirolimus are currently being explored in angioplasty. Paclitaxel acts as an antiproliferative agent and can inhibit fibroblast activity and reduce tissue inflammation [11]. When delivered locally, this reduces fibrosis and cell proliferation that would contribute to restenosis post-dilation [12]. Drug-coated balloons have the potential to reduce overall costs for the healthcare system if they result in a reduction in restenosis rates. While a paclitaxel-eluting balloon dilation may carry a higher initial procedural cost, by achieving long-term patency in a single session, costs associated with long-term biliary catheters can be avoided, such as staffing, sedation, and hospital beds that would be needed for each procedure. In addition, complications such as infection and bleeding can be avoided, and patients would be expected to return to baseline function sooner. However, the anticipated cost savings would need to be formally evaluated in cost-analysis studies. We also included the use of a cutting balloon prior to paclitaxel-coated balloon dilation. Cutting balloons use micro-blades to create linear incisions that allow for controlled crack propagation during balloon dilation. They have been shown to improve both technical success of dilation, approaching success rates of up to 93%, and long-term outcomes compared to plain balloon dilation [13, 14]. In our case, we chose to use a cutting balloon prior to deploying the drug-coated balloon to break the ring of fibrosis with minimal trauma and allows for deeper penetration of paclitaxel into the duct wall to consolidate the mechanical dilation and inhibit restenosis. While risks such as ductal rupture were considered, previously published case series have not reported major traumatic complications [13]. In addition, guidewire access across the stricture was obtained prior to deploying the cutting balloon such that the stricture could be immediately bridged with a biliary catheter even if a rupture occurred. Regarding the safety of paclitaxel, the use of paclitaxel drug-coated balloons has been found to be safe when compared to plain balloon angioplasty in vascular disease [15]. However, it can be argued that paclitaxel’s use in the biliary system is less well-studied and theoretically the possibility of local drug-related toxicity exists. Further study may be warranted to properly establish paclitaxel-coated balloon dilation as a safe alternative to plain balloon dilation. Conclusion Drug-coated balloon dilation is a promising and feasible alternative to plain balloon dilation in treatment of recurrent benign biliary strictures. Further research is needed to confirm which patient populations would benefit best from this option. Author Contributions: MGH Yeo was responsible for data collection and manuscript write-up. H Xiang was responsible for provision of patient case details and manuscript review. Both were responsible for final approval of the manuscript. Conflicts of Interest: There are no conflicts of interest. Ethics Statement: Written informed consent was obtained from the patient for publication of this case report and accompanying images. The patient’s anonymity has been preserved, and all identifying information has been removed to protect their privacy. This case report was conducted in accordance with the principles outlined in the Declaration of Helsinki. Ethical approval was not required as this is a descriptive report of a single clinical case, but all procedures adhered to institutional guidelines for patient confidentiality and data protection. References